Zentiva will release its 3Q consolidated IFRS figures on Monday, October 31. Apart from seasonal effects meaning higher sales and lower margins in 3Q, Zentiva’s results should be positively impacted by the continued focus on higher margin branded products and improved material sourcing, including higher consumption of Active Pharmaceutical Ingredients (APIs) it produces itself. Operating costs should be seasonally below 2Q figures. Nevertheless, we expect a yoy increase in sales&marketing costs categories due to foreign expansion and the promotion of branded products. Lower debt and corporate tax should positively impact the bottom line. At the conference call we will be looking for more details regarding the recent acquisition of Sicomed. A conference call will be held on October 31 at 4:30pm CET (3:30pm UK). Dial-in no.: +44-207 162 0125.
IFRS Consolidated (CZK m) 9M2005 9M2004 % change Consensus
Sales 8,305 7,844 5.9% -
Gross Profit 5,255 4,842 8.5% -
EBIT 2,021 2,000 1.0% -
Pre-tax income 2,030 1,886 7.7% -
Net income 1,460 1,194 22.3% -
EPS (CZK, annualized) 51.0 31.3 63.0% -